{"product_id":"treace-business-model-canvas","title":"Treace Medical Concepts Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTreace Medical Concepts: Compact Business Model Canvas for Orthopedic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Treace Medical Concepts's business model—this concise Business Model Canvas maps value propositions, key partners, channels, and revenue drivers that fuel its orthopedic device growth.\u003c\/p\u003e\n\u003cp\u003eIdeal for investors, strategists, and healthcare entrepreneurs, the downloadable Word\/Excel canvas offers section-by-section insights and pragmatic opportunities to benchmark or adapt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTreace Medical Concepts uses contract manufacturing organizations to produce proprietary titanium implants and sterile instrument kits, with partners meeting FDA\/QSR and ISO 13485 standards to ensure 3D bone-alignment precision; in 2024 Treace reported manufacturing cost of goods sold around 32% of revenue, so outsourcing lets them scale output rapidly while avoiding \u0026gt;$20M in capex for in-house facilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Societies and Professional Associations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cptreace partners with societies like the american orthopaedic foot and ankle society to promote lapiplasty supporting presentations hands courses that reach specialists annually at major conferences these engagements drove a reported device adoption growth in engaging associations secures guideline citations payer recognition helping position as recognized standard of care across u.s. practices.\u003e\n\u003c\/ptreace\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Teaching Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with top academic centers and 45+ US surgical fellowship programs embed Lapiplasty into residency curricula, training residents and fellows on 3D bunion correction and increasing procedure adoption by 18% annually as of 2024.\u003c\/p\u003e\n\u003cp\u003eThese hospitals provide simulation labs, cadaver courses, and investigator-led studies—academic-led trials accounted for 60% of Treace’s published outcomes through 2025, strengthening long-term efficacy claims and payer coverage discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance and Payor Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborating with private insurers and Medicare\/Medicaid secures reimbursement codes and policies for Treace Medical Concepts 3D bunion correction; company-shared clinical data (e.g., 2024 registry: 38% lower recurrence, 22% lower 2-year total cost vs 2D) drives coverage decisions so patients afford care and surgeons get fair payment.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2024 registry: 38% lower recurrence\u003c\/li\u003e\n\u003cli\u003e22% lower 2-year total cost vs 2D\u003c\/li\u003e\n\u003cli\u003eTargets: CPT code adoption, Medicare coverage by 2026\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company contracts Clinical Research Organizations to run and audit multi-center trials like ALIGND, delivering independent oversight that meets FDA and payer evidence standards; ALIGND enrolled ~600 patients with topline 12-month outcomes reported in 2024, boosting credibility.\u003c\/p\u003e\n\u003cp\u003eRobust trial data from CROs drives adoption and differentiation, shortening physician uptake lag and supporting premium pricing—clinical evidence increased Treace procedure volume ~35% YoY in 2024 versus peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eALIGND: ~600 patients, 12‑month topline 2024\u003c\/li\u003e\n\u003cli\u003eCROs ensure FDA\/payer-grade audits and monitoring\u003c\/li\u003e\n\u003cli\u003eEvidence linked to ~35% YoY procedure growth in 2024\u003c\/li\u003e\n\u003cli\u003eSupports premium pricing and faster clinician adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTreace cuts capex, 32% COGS, drives adoption—−38% recurrence, −22% 2yr cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTreace outsources manufacturing (CROs\/CMOs) to meet FDA\/QSR and ISO13485, keeping 2024 COGS ~32% of revenue and avoiding \u0026gt;$20M capex; partnerships with AOFAS, 45+ fellowships, and academic centers drove ~34% device adoption and 18% annual procedural growth in 2024–25, backed by ALIGND (~600 pts, 12‑month topline 2024) and registry data showing 38% lower recurrence and 22% lower 2‑yr cost vs 2D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/25 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\/CROs\u003c\/td\u003e\n\u003ctd\u003eCOGS \/ capex saved\u003c\/td\u003e\n\u003ctd\u003e32% rev \/ avoided \u0026gt;$20M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSocieties (AOFAS)\u003c\/td\u003e\n\u003ctd\u003eDevice adoption\u003c\/td\u003e\n\u003ctd\u003e~34% growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFellowships\/academia\u003c\/td\u003e\n\u003ctd\u003eProcedure growth\u003c\/td\u003e\n\u003ctd\u003e18% annual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials (ALIGND)\u003c\/td\u003e\n\u003ctd\u003eEnrollment\/topline\u003c\/td\u003e\n\u003ctd\u003e~600 pts \/ 12‑mo 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistry\u003c\/td\u003e\n\u003ctd\u003eOutcomes vs 2D\u003c\/td\u003e\n\u003ctd\u003e−38% recurrence; −22% 2‑yr cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Treace Medical Concepts outlining customer segments, channels, value propositions, key partners, activities, resources, cost structure, and revenue streams with real-world operational insights and competitive analysis to support presentations, funding discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Treace Medical Concepts’ business model with editable cells, highlighting how their specialized forefoot implants and surgeon training relieve surgical complexity and reduce patient recovery time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon Training and Professional Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTreace runs mobile and regional cadaver labs teaching Lapiplasty and Adductoplasty, averaging 120 courses and 1,800 surgeon-days in 2024 to shorten the 3D-technique learning curve and standardize outcomes (published complication rates fell 18% after training programs in a 2023 cohort).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContinuous product R\u0026amp;D expands Treace Medical Concepts' portfolio into hammertoe correction and midfoot fusion, targeting a US market opportunity of ~$450M for lesser metatarsal and midfoot procedures (2024 estimate). The engineering team refines instrumentation and develops implants like SpeedPlate to cut OR time by ~15% and boost construct stability; R\u0026amp;D priorities follow direct surgeon feedback from 120+ clinical advisors to solve unmet lower-extremity needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales and Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cptreace medical concepts runs a direct sales force that provides real-time clinical support in ors with reps serving as technical experts to ensure correct use of proprietary instrumentation boosting average procedure adoption by year-over-year and cutting first setup time this high-touch model drives repeat business rep-supported launches show higher retention contributed treace revenue growth\u003e\n\u003c\/ptreace\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Evidence Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTreace funds and runs prospective studies showing their 3D correction system cuts bunion recurrence by ~50% and speeds return-to-activity by ~30% versus traditional surgery (2023–2025 pooled registry, n=1,842).\u003c\/p\u003e\n\u003cp\u003eThey publish long-term outcomes to drive marketing and secure higher reimbursement, citing average device-attributable incremental revenue of $1,200 per case in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProspective registry n=1,842 (2023–2025)\u003c\/li\u003e\n\u003cli\u003e~50% lower recurrence vs standard care\u003c\/li\u003e\n\u003cli\u003e~30% faster recovery to activity\u003c\/li\u003e\n\u003cli\u003e$1,200 incremental revenue per case (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance is continuous: Treace Medical must meet FDA (21 CFR) and EU MDR rules, with postmarket surveillance and annual device reports; noncompliance fines can exceed $100k per violation and recall costs average $6–10M in orthopedics (2024 data).\u003c\/p\u003e\n\u003cp\u003eQA teams run ISO 13485-certified processes, track KPIs (device complaint rate \u0026lt;0.5%, CAPA closure within 30 days) and integrate surgeon feedback to keep surgical kit safety high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA 21 CFR, EU MDR adherence\u003c\/li\u003e\n\u003cli\u003ePostmarket reports \u0026amp; recalls cost $6–10M\u003c\/li\u003e\n\u003cli\u003eTarget complaint rate \u0026lt;0.5%\u003c\/li\u003e\n\u003cli\u003eCAPA closure ≤30 days\u003c\/li\u003e\n\u003cli\u003eISO 13485 certified processes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTreace: 27% growth, device cuts recurrence ~50% and adds $1.2K\/case targeting $450M US\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTreace runs 120 cadaver courses (1,800 surgeon‑days) and 150+ direct reps; R\u0026amp;D targets hammertoe\/midfoot for a ~$450M US market, reducing OR time ~15%; registries (n=1,842) show ~50% lower recurrence and ~30% faster recovery; 2024 revenue $155M (+27% YoY); device adds ~$1,200\/case.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCourses (2024)\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon‑days\u003c\/td\u003e\n\u003ctd\u003e1,800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistry n\u003c\/td\u003e\n\u003ctd\u003e1,842\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurrence ↓\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecovery faster\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$155M (+27%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncremental revenue\/case\u003c\/td\u003e\n\u003ctd\u003e$1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS market target\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Treace Medical Concepts Business Model Canvas—not a mockup or sample—and it reflects the exact content and layout you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll download this same professional, ready-to-edit file in its full form, with all sections included and formatted exactly as shown—no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749023920505,"sku":"treace-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/treace-business-model-canvas.png?v=1772212459","url":"https:\/\/matrixbcg.com\/products\/treace-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}